Joshua Meeks

Urologic Oncologist and Scientist at Northwestern University
K-index:3.7

[Journal of Clinical Investigation @jclinicalinvest]

BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear.

https://t.co/IWGm47vadf
Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG.

The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy.
#BladderCancer #BCGtherapy

[Journal of Clinical Investigation @jclinicalinvest]

@JoshMeeks @Cui_Lab @NUFeinbergMed Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer: https://t.co/s2zqCSVs8b

[Amer. Urol. Assn. @AmerUrological]

Exciting opportunity! The AUA is seeking a highly-qualified member to fill the position of AUA’s next Editor of The Journal of Urology®.

🚨 Apply by June 29, 2026 for consideration!

Learn more here ➡️ https://t.co/cQUCzdwRAJ

#TheVoiceofUrology

[Eugene Pietzak @eugene_pietzak]

Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI

[NEJM @NEJM]

Presented at #ASCO26:

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: https://t.co/UxXUkYwd8Z

Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer https://t.co/XgeWL3lqy6

@ASCO

[Uromigos @Uromigos]

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 https://t.co/1Hnhfxr11A

[Joshua Meeks @JoshMeeks]

@OncBrothers @US_FDA @BijoyTelivala @apolo_andrea @TiansterZhang @PGrivasMDPhD @RenoHemonc @dr_yakupergun @siadaneshmand @shilpaonc @DrYukselUrun It’s a big tent

[Joshua Meeks @JoshMeeks]

@UroDocAsh Congratulations- incredibly well deserved.

[Joshua Meeks @JoshMeeks]

@FaltasLab @BladderCancerUS @BCAN_Research @WeillCornell @Cornell @WCMGUcancer @WCMDeptofMed @WCMEnglanderIPM Happy birthday and congrats on the success !!

[Joshua Meeks @JoshMeeks]

@VigneshPackiam We need @RutgersCancer to open and enroll! 🤞@SWOG

[Joshua Meeks @JoshMeeks]

@ChapinMD @UroCancer @UroOnc @UTMDAnderson @KKBree @nnavai @jdhdavis @DrByronLee @BCottaMD @OLWMD @UroDocAsh @JustinRGregg @lislycherymd @sgswisher @ppisters Congrats @KKBree !

[Joshua Meeks @JoshMeeks]

@IBCG_BladderCA TMT debate on radiation toxicity #AUA26

[Joshua Meeks @JoshMeeks]

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

[Joshua Meeks @JoshMeeks]

Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology

[Joshua Meeks @JoshMeeks]

@MaxKates NDV01. Gel- gem-doce Vs obs for IR. Hard to know if obs is the best control.

[Joshua Meeks @JoshMeeks]

MR3🌑 ErdaiDRS. BCG unresponsive. (It’s like SR5-> FGFR3)

[Joshua Meeks @JoshMeeks]

MR2🌑 FGFR3 agnostic. Ablative (noTURBT) for IR. results coming.

[Joshua Meeks @JoshMeeks]

TIP#5 Tyra-300 IR NMIBC. oral FGFR3

[Joshua Meeks @JoshMeeks]

TIP#3 Enlighted Ph3. VTP for UTUC. very reasonable response for LG UTUC